Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients

202354 citationsJournal Articlehybrid Open Access

Authors

Xu Yang · Chinese Academy of Medical Sciences & Peking Union Medical College

Bowen Chen · Chinese PLA General Hospital

Yanyu Wang · Peking Union Medical College Hospital

Yunchao Wang · Peking Union Medical College Hospital

Junyu Long · Chinese Academy of Medical Sciences & Peking Union Medical College

Nan Zhang · Chinese Academy of Medical Sciences & Peking Union Medical College

Abstract

This real-world study of lenvatinib plus PD-1 inhibitor treatment demonstrated long survival and considerable ORRs and DCRs in uHCC patients in China. The tolerability of combination therapy was acceptable but must be monitored closely.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Renal cell carcinoma treatment Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology International

Volume 17, Issue 3, pp. 709-719

DOI: 10.1007/s12072-022-10480-y

Field-Weighted Citation Impact: 11.15